A5077318602- Immune Cell Function and Interaction
- Cancer Treatment and Pharmacology
- HIV Research and Treatment
- Multiple Myeloma Research and Treatments
- Neonatal Respiratory Health Research
- Ubiquitin and proteasome pathways
- Immune responses and vaccinations
- Protein Degradation and Inhibitors
- T-cell and B-cell Immunology
- Pancreatic and Hepatic Oncology Research
- Phagocytosis and Immune Regulation
- Congenital heart defects research
- Cancer Immunotherapy and Biomarkers
- Lymphatic System and Diseases
- Mosquito-borne diseases and control
- Cytomegalovirus and herpesvirus research
- Viral Infections and Vectors
Emory University
2019
Ragon Institute of MGH, MIT and Harvard
2017-2018
National Central University
2013
HIV-1 causes a chronic, incurable disease due to its persistence in CD4+ T cells that contain replication-competent provirus, but exhibit little or no active viral gene expression and effectively resist combination antiretroviral therapy (cART). These latently infected represent an extremely small proportion of all circulating possess remarkable long-term stability typically persist throughout life, for reasons are not fully understood. Here we performed massive single-genome,...
Pancreatic ductal adenocarcinoma (PDAC) has dismal 5-year survival (<9%). We hypothesize that exposure of tumors to conventional therapies may preferentially modulate immune biomarkers in the tumor microenvironment PDAC. PDAC patients who underwent upfront surgical resection or received neoadjuvant FOLFIRINOX with without radiotherapy followed by were selected for study. Total expression immunologically relevant transcripts and spatially resolved proteins was quantitated using multiplexed...
LYVE-1 (also termed CRSBP-1), a 120-kDa disulfide-linked dimeric type I membrane glycoprotein, is specific marker for lymphatic endothelial cells (LECs) and exhibits multiple ligand (hyaluronic acid growth factors/cytokines) binding activity in mammals. Recent studies indicate that LYVE-1/CRSBP-1 ligands (VEGF-A165, PDGF-BB, oligopeptides containing the cell-surface retention sequence (CRS) motifs of VEGF-A165 PDGF-BB) induce opening intercellular junctions vitro vivo. To determine function...
Abstract Multiple myeloma (MM) is the second most common hematologic malignancy. In 2017, MM accounted for approximately 30,770 new diagnoses and 12770 deaths in US. Although, advancements treatment options have increased survival rates life expectancy, remains incurable due to development of resistance. Venetoclax a highly selective, potent BCL-2 antagonist, currently phase I/II trials FDA approved CLL patients exhibiting 17p deletion. effective eliciting cell death as single agent subset...
Multiple myeloma (MM) is the second most common hematologic malignancy. In 2017, MM accounted for approximately 30,770 new diagnoses and 12770 deaths in US. Although, advancements treatment options have increased survival rates life expectancy, remains incurable due to development of resistance. Venetoclax a highly selective, potent BCL-2 antagonist, currently phase I/II trials FDA approved CLL patients exhibiting 17p deletion. effective eliciting cell death as single agent subset with...